After the rapid development of the cell therapy industry in recent years, the CAR-T product market in our country has gradually begun to harvest fruit. Following the approval of Fosun Kat's

 CAR T cell product (Akilencel injection), the product of Pharming Junol (Reakilencel injection) is also about to be approved.

In just half a year, China will usher in two new CAR-T drugs. In addition, Cilta-cel for relapsed or refractory multiple myeloma, which is cooperated by Nanjing Legends and Johnson & Johnson,

 is currently receiving priority review by the US FDA and accelerated evaluation by the EU EMA. This product has achieved an objective remission rate of 98% with bright clinical trial data

 (long-term follow-up of 18 months at the interim stage of 1B-2). Overall survival OS is 81%) directly for the domestic cell therapy market to draw a strong brush.

The CAR T cell therapy market is hot at the right time. However, even though CAR T cell products have achieved remarkable results in the treatment of hematologic malignancies, they face

 many challenges in the treatment of solid malignancies. In addition, at present, the global pipeline of CAR T cell product research is like "an ocean full of red flags", and the patent "swamp"

 currently has invisibly limited the pace of many CAR T companies.

As another member of the "general" of immune cells, macrophages have always been favored by scientific researchers. The remarkable performance of macrophages in the treatment of 

solid malignant tumors has also attracted countless researchers to Call for it. Studies have shown that macrophages modified with specific CARs (CAR-M) can achieve precise attack on tumor 

cells and avoid injury to innocent people, and can also improve the phagocytic activity of macrophages to tumors and the ability of antigen presentation. The emergence of CAR-M opens up

 new possibilities for the treatment of solid malignant tumors.

As a pioneer in the field of CAR-M therapy in China, RocRock Biotechnology (Shenzhen) Co., LTD. (hereinafter referred to as "Kunshi Biology") is committed to creating a closed-loop industrial

 chain model with macrophage research as the core, focusing on the layout of macrophage chimeric antigen receptor therapy to promote the application of macrophages in clinical and 

anti-aging fields. It is understood that Kunshi Biology has established a macrophage targeted treatment solid tumor platform, a macrophage secretion platform and a macrophage lineage 

differentiation screening database, with a rich R&D pipeline, and a core competitiveness in macrophage targeted solid tumor.

Recently, RocRock Biology won the recognition of its mentor and the industry with its innovation project of "Macrophage drugs targeting solid tumors" in the "2021 'Maker Guangdong' 

Biomedical smes Innovation and Entrepreneurship Competition" sponsored by Guangdong Medical Valley.

Professor Yin Xiushan, founder & Chairman of RocRock Biology, introduced to the artery network that at present, RocRock Biology is mainly promoting the research of CAR-M treatment

 products in the field of breast cancer and stomach cancer, and the related product pipeline is currently in the pre-clinical research stage, and the company is committed to achieving the

 successful listing of two innovative drugs in 5-6 years.

More than 10 years later, the two Academy of Military Sciences doctors together again,

A total of "words" entrepreneurship

RocRock Biology was incubated in Berlin, Germany, and founded in Pengcheng Shenzhen in 2021. The company is led by Professor Yin Xiushan, a returned Chinese scientist from Europe,

 and a number of scientific research institutions and pharmaceutical companies from the field of life sciences Karolinska Institutet in Sweden, the European Molecular Biology Laboratory,

 the National Center for Molecular Medicine in Germany, Hong Kong Baptist University, etc., relying on its scientific research team for more than 10 years of cutting-edge multidisciplinary

 research results founded.

Professor Yin Xiushan, founder & Chairman of RocRock Biology

Professor Yin has worked in the Academy of Military Medical Sciences, the European Molecular Biology Laboratory (EMBL), the University of Cologne Medical School, the Marx-Delbruck 

Center for Molecular Medicine and the Karolinska Institute in Sweden, and has more than 15 years of experience in cellular drug research. In the previous research career, he has won many

 awards, has published more than 20 SCI articles, 12 patents, completed product development and transformation 4 projects; He has presided over 8 international and domestic funds with

 a total fund of 40 million yuan.

In addition to being a research scholar, Professor Yin is also a serial entrepreneur. In 2018 and 2019, he founded Turing Medical GMBH and Biaotec Biomedical Group, which focus on organ

 medicine and new stem cell drugs, respectively. As the same collaborative system but independent of each other, the three companies can collaborate with each other and share specific

 resources, thus promoting the collaborative development of the companies, achieving "1 (past resources) +1 (current resources) > 2".

Prof. Zhang Ci, special academic Advisor of RocRock, has been mainly engaged in the design and application of Cell circuits based on macrophages for many years, and has published 10 

SCI papers in journals such as Cell Research, Gastroenterology, Circulation as the first or corresponding author. Applied for 2 national invention patents. He undertook national key research

 and development projects, National Natural Science Foundation and Beijing Natural Science Foundation projects, and won the first prize of Beijing Science and Technology Award as a major

 contributor.

What unites the two professors is their status as alumni of the Academy of Military Medical Sciences. Professor Yin introduced to the artery network that the two of them had studied together

 at the Academy of Military Medical Sciences for a doctorate and were teachers and brothers of a scientific research team. Years of acquaintance have made the two former master brothers

 become close business partners.

CNS Grand Slam team's achievement transformation, patent for "king"

The creation of Kunshi organism is based on the transformation of the research results of the team's cutting-edge exploration in the direction of macrophage research for more than 10 years.

The core team members of RocRock Biology also have hardcore international academic background and industrial background. The research achievements of 

the entire core team of Kunshi BIOLOGY can be described as winning the Grand slam of CNS, publishing a series of important results in the world's top

 journals, including CELL, NATURE, SCIENCE, NATURE MEDICINE, NATURE CELL BIOLOGY and other journals, with a total impact factor of more than 1000. 

Team members are from the European Molecular Biology Laboratory, the German National Center for Molecular Medicine, Hong Kong Baptist University and 

many other international scientific research institutions and well-known pharmaceutical companies, each with the corresponding patented technology and 

resource ties to help the rapid development of Kunshi biology.

"Patents are our biggest trump card." Professor Yin Xiushan said that Kunshi Biology has specially set up a core patent team and a team of intellectual property lawyers, "which determines

 whether the company's future products can go to sea smoothly."

How to "fight" solid tumors, CAR-macrophages "have words"

tumorassociated macrophages (TAMs) are widely found in the solid tumor microenvironment (TME), and play an important role in phagocytosis and killing pathogens, processing and 

presenting antigens. Given the unique effecting function of TAMs and their ability to penetrate tumors, the researchers used CARs biotechnology to engineer human macrophages so

 that their phagocytic activity directly acts on tumors.

Similar to CAR-T and CAR-NK cells, CAR-M cells are composed of extracellular signaling domains that recognize specific tumor antigens, transmembrane regions, and intracellular activation

signaling regions. At present, the extracellular signaling domain is mainly studied in several common tumor targets, such as CD19 and HER2.

Unlike CAR-T cells, CAR-M cells have three main advantages:

1) T cells cannot enter the tumor environment due to the physical barrier formed by the matrix around tumor cells, or they cannot exert their effect due to immunosuppression after 

infiltration; And macrophages can clearly invade the tumor environment. TAM plays an important role in tumor invasion, metastasis, immunosuppression and angiogenesis. CAR-M can reduce 

the proportion of TAM, affect the cell phenotype of TAM, and play a positive role in the treatment of tumor.

2) In addition to phagocytosis of tumor cells, CAR-M also has the function of promoting antigen presentation and enhancing T cell killing.

3) Compared with CAR-T, CAR-M has limited cycle time and less non-tumor targeting toxicity.

To date, one clinical trial based on the CAR-M strategy has been approved by the FDA - CT-0508, a drug candidate developed by CARISMA Therapeutics to treat patients with 

relapsed/refractory HER2 overexpression tumors with anti-HER2 CAR M, which is currently in Phase I clinical trials.

Domestic CAR-M related research mostly stays in the scientific research stage, and the industrial track is still a blue ocean

According to Professor Yin Xiushan, the current domestic research on CAR-M treatment strategy is still in the stage of scientific exploration, and there are few industrial transformations. 

RocRock Biology, as a pioneer in domestic CAR-M treatment companies, will undoubtedly take the lead in this new fertile soil. At the same time, Kunshi Biology said that it hopes that more 

like-minded talents and teams will join the track in the future to jointly promote the industrial transformation of CAR-M research.

"In fact, in the next 20 or 30 years, the development speed and process of CAR-M and CAR-T are very similar, but it is a matter of short-term development." Professor Yin said that the future 

CAR-M research will also be like the development momentum of the CAR-T industry, becoming a wider and deeper hot track, and more solid tumor patients can also enjoy more effective 

emerging treatment options.

At present, RocRock Biology has reached an agreement to jointly build a macrophage research and development center in Beijing and share the Jiangxi GMP production base of cell drugs, 

in order to promote the company's two core products into phase I clinical as soon as possible. At the same time, the company's cooperation with domestic and foreign hospitals and 

international research institutes is also in an orderly way. In addition, Kunshi Bio is currently planning to build a wholly-owned subsidiary in the Berlin Biotech Industrial Park, Germany,

 to further coordinate its development in Europe and its strategic cooperation with pharmaceutical giants such as Bayer and Novartis.

The road is blocked and long, the future can be expected

Although CAR-M has great potential to become a powerful tumor immunotherapy, many problems still need to be overcome to achieve the desired effect: for example, the proliferation of 

macrophages; Transfection is difficult; Most of the exogenous macrophages will remain in the liver through the lungs, which is not conducive to the treatment of cancer and the more complex

 tumor microenvironment in the human body. However, with the addition of more and more outstanding talents and the establishment of high-quality enterprises, we are very much looking

 forward to the progress and breakthrough of CAR-M in solid tumors. The international progress of CAR-M research also shows us this.

RocRock biological team photo

As an industry pioneer in the field of CAR-M cells in China,RocRock Biology is expected to take the lead in opening a new chapter in the field of CAR-M, and then bring good news to more 

patients with solid tumors. Arterinet will also continue to track the growth of CAR-M cell therapy startups.

About 2021 Maker Guangdong · Biomedicine Special Competition

The 2021 "Maker Guangdong" Bio-pharmaceutical SME Innovation and Entrepreneurship Competition is guided by Guangdong Provincial Department of Industry and Information Technology,

 Guangdong Provincial Department of Finance, Dongguan Municipal People's Government, and hosted by Guangdong Medical Valley. Since the competition was held, it has focused on the 

field of biomedicine and explored high-quality projects in the prevention and control of COVID-19 and health protection. Nearly 200 projects have been excavated, and most of the 

recommended projects have won awards in the provincial finals, and Guangdong Medical Valley has won the "Best Organization Unit in 2020".

Founded in 2014, Guangdong Medical Valley is a new medical cluster service provider of Zhongchuang Group, focusing on the investment incubation platform of biomedical and medical 

device industry. Currently, it has been distributed in Guangzhou, Zhuhai and other places, with a total area of about 530,000 square meters built or under construction. It is a national science 

and technology enterprise incubator, a key construction project in Guangdong Province and a demonstration park in Guangzhou. Guangdong Medical Valley has always been adhering to the 

concept of "industrial cluster is the most important starting point for the innovation and development of the medical industry", adhering to the development mode of integrating medical 

industry incubator, medical project equity investment and comprehensive supporting services for the medical industry, and deeply cultivating the Greater Bay Area, committed to building a

 world-class international medical industry innovation center.